Clinical Advances and Perspectives in Targeted Radionuclide Therapy
Pharmaceutics · 14.06.2023 · 15 (6) · 1733
DOI: 10.3390/pharmaceutics15061733 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 14.06.2023. Verfasst von Nicolas Lepareur und 3 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Cancer Center Eugène Marquis, 35000 Rennes, France. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 273 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Labex IRON, Cancéropôle Grand Ouest.
Abstract (Originalsprache)
Targeted radionuclide therapy has become increasingly prominent as a nuclear medicine subspecialty. For many decades, treatment with radionuclides has been mainly restricted to the use of iodine-131 in thyroid disorders. Currently, radiopharmaceuticals, consisting of a radionuclide coupled to a vector that binds to a desired biological target with high specificity, are being developed. The objective is to be as selective as possible at the tumor level, while limiting the dose received at the healthy tissue level. In recent years, a better understanding of molecular mechanisms of cancer, as well as the appearance of innovative targeting agents (antibodies, peptides, and small molecules) and the availability of new radioisotopes, have enabled considerable advances in the field of vectorized internal radiotherapy with a better therapeutic efficacy, radiation safety and personalized treatments. For instance, targeting the tumor microenvironment, instead of the cancer cells, now appears particularly attractive. Several radiopharmaceuticals for therapeutic targeting have shown clinical value in several types of tumors and have been or will soon be approved and authorized for clinical use. Following their clinical and commercial success, research in that domain is particularly growing, with the clinical pipeline appearing as a promising target. This review aims to provide an overview of current research on targeting radionuclide therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Comprehensive Cancer Center Eugène Marquis, 35000 Rennes, France.
- Inserm, INRAE, Institut NUMECAN (Nutrition, Métabolismes et Cancer)-UMR 1317, Univ Rennes, 35000 Rennes, France.
- Nuclear Medicine Department, Nantes University Hospital, 44000 Nantes, France.
- Inserm, CNRS, CRCI2NA (Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers)-UMR 1307, Université de Nantes, ERL 6001, 44000 Nantes, France.
- Groupement d'Intérêt Public ARRONAX, 1 Rue Aronnax, 44817 Saint Herblain, France.
ORCID-Profile: Nicolas Lepareur, Barthélémy Ramée, Mickaël Bourgeois
Förderung
- Labex IRON
- Cancéropôle Grand Ouest
Zitieren
APA
Lepareur, N., Ramée, B., Mougin-Degraef, M., & Bourgeois, M. (2023). Clinical Advances and Perspectives in Targeted Radionuclide Therapy. Pharmaceutics, 15(6), 1733. https://doi.org/10.3390/pharmaceutics15061733
Vancouver
Lepareur N, Ramée B, Mougin-Degraef M, Bourgeois M. Clinical Advances and Perspectives in Targeted Radionuclide Therapy. Pharmaceutics. 2023;15(6):1733. doi:10.3390/pharmaceutics15061733
BibTeX
@article{Lepareur2023,
author = {Lepareur, Nicolas and Ramée, Barthélémy and Mougin-Degraef, Marie and Bourgeois, Mickaël},
title = {Clinical Advances and Perspectives in Targeted Radionuclide Therapy},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {6},
pages = {1733},
doi = {10.3390/pharmaceutics15061733}
}
EUVIMED